12.23
                                            Schlusskurs vom Vortag:
              $12.84
            Offen:
              $12.77
            24-Stunden-Volumen:
                973.67K
            Relative Volume:
              0.83
            Marktkapitalisierung:
                $647.68M
            Einnahmen:
              $1.02B
            Nettoeinkommen (Verlust:
              $-757.20M
            KGV:
              -0.8287
            EPS:
                -14.76
            Netto-Cashflow:
                $-257.90M
            1W Leistung:
              +23.73%
            1M Leistung:
              +36.63%
            6M Leistung:
                +125.68%
            1J Leistung:
              +33.02%
            Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
                  
                      Emergent Biosolutions Inc
                    
                Sektor
                  Telefon
                  
                      240-631-3200
                    
                Adresse
                  
                      300 PROFESSIONAL DR, GAITHERSBURG, MD
                    
                Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                EBS
                            
                             Emergent Biosolutions Inc | 12.14 | 676.67M | 1.02B | -757.20M | -257.90M | -14.76 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 143.02 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.43 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.245 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.09 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 448.03 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy | 
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy | 
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy | 
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight | 
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold | 
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy | 
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight | 
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold | 
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral | 
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy | 
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold | 
| 2021-05-05 | Herabstufung | Argus | Buy → Hold | 
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy | 
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy | 
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral | 
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight | 
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral | 
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy | 
| 2019-09-12 | Eingeleitet | Guggenheim | Buy | 
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform | 
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy | 
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy | 
| 2018-06-13 | Eingeleitet | Argus | Buy | 
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform | 
| 2018-01-24 | Eingeleitet | Goldman | Neutral | 
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy | 
| 2016-06-28 | Bestätigt | Singular Research | Buy | 
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy | 
| 2016-03-28 | Eingeleitet | Singular Research | Buy | 
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform | 
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy | 
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy | 
| 2011-01-10 | Bestätigt | Wedbush | Outperform | 
| 2010-11-05 | Bestätigt | Wedbush | Outperform | 
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy | 
| 2010-08-06 | Bestätigt | Caris & Company | Buy | 
                    Alle ansehen
                     
                  
                Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Is Emergent BioSolutions Inc. stock dividend yield sustainableJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
What sentiment indicators say about Emergent BioSolutions Inc. stock2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
symbol__ Stock Quote Price and Forecast - CNN
How Emergent BioSolutions Inc. stock benefits from tech adoptionJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Emergent BioSolutions Reports Strong Q3 2025 Results - The Globe and Mail
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendations2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Will Emergent BioSolutions Inc. stock return to pre crisis levelsPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results, Beats Expectations By $1.18 EPS - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Emergent BioSolutions (EBS) Earnings Transcript - The Globe and Mail
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge - MSN
Gaithersburg-based Emergent Biosolutions reports Q3 earnings - Maryland Daily Record
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Will Emergent BioSolutions Inc. benefit from macro trendsBull Run & Reliable Volume Spike Trade Alerts - newser.com
Will Emergent BioSolutions Inc. stock sustain high P E ratiosJuly 2025 Gainers & Precise Buy Zone Identification - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedMarket Growth Summary & Verified Entry Point Signals - newser.com
Emergent Biosolutions: Q3 Earnings Snapshot - Stamford Advocate
Understanding Emergent BioSolutions Inc.’s price movementWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Will breakout in Emergent BioSolutions Inc. lead to full recoveryEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockJuly 2025 Update & Safe Entry Zone Identification - newser.com
Is Emergent BioSolutions Inc. a candidate for recovery playGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Emergent Biosolutions earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Why Emergent BioSolutions Inc. stock remains resilientJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates - sharewise.com
EBS Boosts Financial Outlook for Fiscal Year - GuruFocus
Emergent BioSolutions Inc Bottom Line Drops In Q3 - Nasdaq
Emergent BioSolutions Raises Full-Year Revenue Guidance - TipRanks
Emergent BioSolutions Inc Reports Q3 2025 Earnings: EPS of $0.91 - GuruFocus
Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook - TradingView
Emergent BioSolutions Reports Third Quarter 2025 Financial Results - The Manila Times
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Investors in Emergent BioSolutions (NYSE:EBS) have unfortunately lost 90% over the last five years - Yahoo Finance
Chart based exit strategy for Emergent BioSolutions Inc.Watch List & High Accuracy Investment Entry Signals - newser.com
Why Emergent BioSolutions Inc. stock could rally in 20252025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Emergent Biosolutions Q3 earnings call set to reveal financial results - Traders Union
Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit - Stocktwits
Emergent (NYSE: EBS): 45% say U.S. unprepared, 65% see rising bioattack risk - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App